(PDF) Cost Per Responder of Apremilast Versus Etanercept

Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.2589

Full Text

Open PDF

Abstract

Available in full text

Date

November 1, 2014

Authors

T. Tencer

Z. Clancy

F. Zhang

Publisher

Elsevier BV

Related search

Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective

English

Pms27 - Secukinumab Versus Adalimumab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

English

Pss13 - Budget Impact Analysis of Apremilast in Patients With Active Psoriatic Arthritis in Greece

English

Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan

English

PMS82 US Treatment Patterns in Psoriatic Arthritis Newly Initiated on Etanercept or Adalimumab

English

Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

English

Pms54 - Cost-Effectiveness Analysis of Etanercept as First Line of Treatment in Colombian Patients With Psoriatic Arthritis

English

PMS23 Cost Per Treated Rheumatoid Arthritis (RA) Patient for Etanercept, Adalimumab and Infliximab: A Retrospective Claims Database Analysis

English

Comparison of Disease Status and Outcomes of Patients With Psoriatic Arthritis (PSA) Receiving Adalimumab or Etanercept Monotherapy in the United States (US)

English

Amanote Research

Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.2589

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective

Pms27 - Secukinumab Versus Adalimumab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

Pss13 - Budget Impact Analysis of Apremilast in Patients With Active Psoriatic Arthritis in Greece

Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan

PMS82 US Treatment Patterns in Psoriatic Arthritis Newly Initiated on Etanercept or Adalimumab

Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

Pms54 - Cost-Effectiveness Analysis of Etanercept as First Line of Treatment in Colombian Patients With Psoriatic Arthritis

PMS23 Cost Per Treated Rheumatoid Arthritis (RA) Patient for Etanercept, Adalimumab and Infliximab: A Retrospective Claims Database Analysis

Comparison of Disease Status and Outcomes of Patients With Psoriatic Arthritis (PSA) Receiving Adalimumab or Etanercept Monotherapy in the United States (US)